Cargando…

The Effect of Antihypertensive Drugs on NADH in Newly Diagnosed Primary Hypertension

BACKGROUND: Some antihypertensive medications alter cellular energy production, presumably by modification of the mitochondrial function. In vivo studies of such effects are challenging in humans. We applied a noninvasive forearm skin measurement of the 460-nm fluorescence specific for the reduced f...

Descripción completa

Detalles Bibliográficos
Autores principales: Pawlak-Chomicka, Regina, Krauze, Tomasz, Uruski, Pawel, Piskorski, Jaroslaw, Wykretowicz, Andrzej, Tykarski, Andrzej, Guzik, Przemyslaw
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989586/
https://www.ncbi.nlm.nih.gov/pubmed/35402043
http://dx.doi.org/10.1155/2022/6159883
_version_ 1784683209104031744
author Pawlak-Chomicka, Regina
Krauze, Tomasz
Uruski, Pawel
Piskorski, Jaroslaw
Wykretowicz, Andrzej
Tykarski, Andrzej
Guzik, Przemyslaw
author_facet Pawlak-Chomicka, Regina
Krauze, Tomasz
Uruski, Pawel
Piskorski, Jaroslaw
Wykretowicz, Andrzej
Tykarski, Andrzej
Guzik, Przemyslaw
author_sort Pawlak-Chomicka, Regina
collection PubMed
description BACKGROUND: Some antihypertensive medications alter cellular energy production, presumably by modification of the mitochondrial function. In vivo studies of such effects are challenging in humans. We applied a noninvasive forearm skin measurement of the 460-nm fluorescence specific for the reduced form of nicotinamide adenine dinucleotide (NADH) to study the 6-week effects of four different antihypertensive medications on mitochondrial function using the Flow-Mediated Skin Fluorescence (FMSF). METHODS: In a prospective open-label study, we compared the long-term effects of a 6-week treatment with either amlodipine (5 mg), perindopril (5 mg), nebivolol (5 mg), or metoprolol (50 mg) on the dynamic flow-mediated changes in the skin NADH content in 76 patients (29 women) with untreated primary arterial hypertension (HA). Patients underwent 24-hour ambulatory blood pressure monitoring. To study mitochondrial function, the FMSF was measured at rest, during 100-second ischemia and postischemic reperfusion. The control group consisted of 18 healthy people (7 women). RESULTS: There were no significant differences in the FMSF parameters between the control and the study group before medication. After the 6-week treatment, all drugs similarly reduced blood pressure. Neither amlodipine, perindopril, nor nebivolol changed the flow-mediated 460-nm skin fluorescence significantly. However, metoprolol raised this fluorescence at rest, during ischemia and reperfusion (P at most <0.05), indicating an increase in the total NADH skin content. CONCLUSION: Amlodipine, perindopril, and nebivolol appear neutral for the skin NADH content during the 6-week antihypertensive treatment. Similar treatment with metoprolol increased skin NADH at rest, during ischemia and reperfusion, probably due to an effect on microcirculation and altered mitochondrial function. Explanation of the potential mechanisms behind metoprolol influence on the skin NADH metabolism requires further investigation.
format Online
Article
Text
id pubmed-8989586
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-89895862022-04-08 The Effect of Antihypertensive Drugs on NADH in Newly Diagnosed Primary Hypertension Pawlak-Chomicka, Regina Krauze, Tomasz Uruski, Pawel Piskorski, Jaroslaw Wykretowicz, Andrzej Tykarski, Andrzej Guzik, Przemyslaw Cardiol Res Pract Research Article BACKGROUND: Some antihypertensive medications alter cellular energy production, presumably by modification of the mitochondrial function. In vivo studies of such effects are challenging in humans. We applied a noninvasive forearm skin measurement of the 460-nm fluorescence specific for the reduced form of nicotinamide adenine dinucleotide (NADH) to study the 6-week effects of four different antihypertensive medications on mitochondrial function using the Flow-Mediated Skin Fluorescence (FMSF). METHODS: In a prospective open-label study, we compared the long-term effects of a 6-week treatment with either amlodipine (5 mg), perindopril (5 mg), nebivolol (5 mg), or metoprolol (50 mg) on the dynamic flow-mediated changes in the skin NADH content in 76 patients (29 women) with untreated primary arterial hypertension (HA). Patients underwent 24-hour ambulatory blood pressure monitoring. To study mitochondrial function, the FMSF was measured at rest, during 100-second ischemia and postischemic reperfusion. The control group consisted of 18 healthy people (7 women). RESULTS: There were no significant differences in the FMSF parameters between the control and the study group before medication. After the 6-week treatment, all drugs similarly reduced blood pressure. Neither amlodipine, perindopril, nor nebivolol changed the flow-mediated 460-nm skin fluorescence significantly. However, metoprolol raised this fluorescence at rest, during ischemia and reperfusion (P at most <0.05), indicating an increase in the total NADH skin content. CONCLUSION: Amlodipine, perindopril, and nebivolol appear neutral for the skin NADH content during the 6-week antihypertensive treatment. Similar treatment with metoprolol increased skin NADH at rest, during ischemia and reperfusion, probably due to an effect on microcirculation and altered mitochondrial function. Explanation of the potential mechanisms behind metoprolol influence on the skin NADH metabolism requires further investigation. Hindawi 2022-03-31 /pmc/articles/PMC8989586/ /pubmed/35402043 http://dx.doi.org/10.1155/2022/6159883 Text en Copyright © 2022 Regina Pawlak-Chomicka et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Pawlak-Chomicka, Regina
Krauze, Tomasz
Uruski, Pawel
Piskorski, Jaroslaw
Wykretowicz, Andrzej
Tykarski, Andrzej
Guzik, Przemyslaw
The Effect of Antihypertensive Drugs on NADH in Newly Diagnosed Primary Hypertension
title The Effect of Antihypertensive Drugs on NADH in Newly Diagnosed Primary Hypertension
title_full The Effect of Antihypertensive Drugs on NADH in Newly Diagnosed Primary Hypertension
title_fullStr The Effect of Antihypertensive Drugs on NADH in Newly Diagnosed Primary Hypertension
title_full_unstemmed The Effect of Antihypertensive Drugs on NADH in Newly Diagnosed Primary Hypertension
title_short The Effect of Antihypertensive Drugs on NADH in Newly Diagnosed Primary Hypertension
title_sort effect of antihypertensive drugs on nadh in newly diagnosed primary hypertension
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989586/
https://www.ncbi.nlm.nih.gov/pubmed/35402043
http://dx.doi.org/10.1155/2022/6159883
work_keys_str_mv AT pawlakchomickaregina theeffectofantihypertensivedrugsonnadhinnewlydiagnosedprimaryhypertension
AT krauzetomasz theeffectofantihypertensivedrugsonnadhinnewlydiagnosedprimaryhypertension
AT uruskipawel theeffectofantihypertensivedrugsonnadhinnewlydiagnosedprimaryhypertension
AT piskorskijaroslaw theeffectofantihypertensivedrugsonnadhinnewlydiagnosedprimaryhypertension
AT wykretowiczandrzej theeffectofantihypertensivedrugsonnadhinnewlydiagnosedprimaryhypertension
AT tykarskiandrzej theeffectofantihypertensivedrugsonnadhinnewlydiagnosedprimaryhypertension
AT guzikprzemyslaw theeffectofantihypertensivedrugsonnadhinnewlydiagnosedprimaryhypertension
AT pawlakchomickaregina effectofantihypertensivedrugsonnadhinnewlydiagnosedprimaryhypertension
AT krauzetomasz effectofantihypertensivedrugsonnadhinnewlydiagnosedprimaryhypertension
AT uruskipawel effectofantihypertensivedrugsonnadhinnewlydiagnosedprimaryhypertension
AT piskorskijaroslaw effectofantihypertensivedrugsonnadhinnewlydiagnosedprimaryhypertension
AT wykretowiczandrzej effectofantihypertensivedrugsonnadhinnewlydiagnosedprimaryhypertension
AT tykarskiandrzej effectofantihypertensivedrugsonnadhinnewlydiagnosedprimaryhypertension
AT guzikprzemyslaw effectofantihypertensivedrugsonnadhinnewlydiagnosedprimaryhypertension